{
    "root": "2f9bfd2f-129e-a52a-e063-6294a90a9856",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pantoprazole Sodium",
    "value": "20250305",
    "ingredients": [
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "GLYCERYL DIBEHENATE",
            "code": "R8WTH25YS2",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13038"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)",
            "code": "74G4R6TH13",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "PANTOPRAZOLE SODIUM",
            "code": "6871619Q5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50270"
        }
    ],
    "indications": {
        "text": "pantoprazole sodium delayed-release tablets , usp indicated :",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "indication dose frequency short-term treatment erosive esophagitis associated gerd ( 2.1 ) adults 40 mg daily 8 wks children ( 5 years older ) \u2265 15 kg < 40 kg 20 mg daily 8 wks \u2265 40 kg 40 mg maintenance healing erosive esophagitis ( 2.1 ) adults 40 mg daily controlled extend beyond 12 months pathological hypersecretory conditions including zollinger-ellison syndrome ( 2.1 ) adults 40 mg twice daily full prescribing information instructions",
        "doid_entities": [
            {
                "text": "esophagitis (DOID:11963)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11963"
            },
            {
                "text": "gerd (DOID:8534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8534"
            },
            {
                "text": "zollinger-ellison syndrome (DOID:0050782)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050782"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "zollinger-ellison syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_913"
            }
        ]
    },
    "warningsAndPrecautions": "supplied pantoprazole sodium delayed-release tablets , usp supplied 40 mg white off-white , oval-shaped coated tablet , debossed `` 17 `` one side available follows : boxes 10 x 10 ud 100 ndc 63739-564-10 storage store pantoprazole sodium delayed-release tablets , usp 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "pantoprazole contraindicated patients known hypersensitivity component formulation substituted benzimidazole . hypersensitivity may include anaphylaxis , anaphylactic shock , angioedema , bronchospasm , acute tubulointerstitial nephritis , urticaria [ ( 5.2 ) ( 6 ) ] . \u200b proton pump inhibitors ( ppis ) , including pantoprazole , contraindicated patients receiving rilpivirine-containing products [ ( 7 ) ] .",
    "indications_original": "Pantoprazole Sodium Delayed-Release Tablets, USP are indicated for:",
    "contraindications_original": "Indication Dose Frequency Short-Term Treatment of Erosive Esophagitis Associated With GERD ( 2.1 ) Adults 40 mg Once Daily for up to 8 wks Children (5 years and older) \u2265 15 kg to < 40 kg 20 mg Once Daily for up to 8 wks \u2265 40 kg 40 mg Maintenance of Healing of Erosive Esophagitis ( 2.1 ) Adults 40 mg Once Daily Controlled studies did not extend beyond 12 months Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome ( 2.1 ) Adults 40 mg Twice Daily See full prescribing information for administration instructions",
    "warningsAndPrecautions_original": "How Supplied\n                     \nPantoprazole Sodium Delayed-Release Tablets, USP are supplied as 40 mg white to off-white, oval-shaped coated tablet,\n  \ndebossed with \"17\" on one side and are available as follows:\n  \nBoxes of 10 x 10 UD 100 NDC 63739-564-10\n \n                  \n                  \n                     Storage\n                     \nStore Pantoprazole Sodium Delayed-Release Tablets, USP at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C\n  \n(59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Pantoprazole is contraindicated in patients with known hypersensitivity to any component of the formulation or any\n                  \n                  substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema,\n  \nbronchospasm, acute tubulointerstitial nephritis, and urticaria\n   [see Warnings and Precautions (5.2) and Adverse Reactions (6)].\u200b\n  \n                  \n                  \n                  \n                     Proton pump inhibitors (PPIs), including Pantoprazole, are contraindicated in patients receiving rilpivirine-containing products \n   [see Drug Interactions ( \n    7)].",
    "drug": [
        {
            "name": "Pantoprazole Sodium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50270"
        }
    ]
}